http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2750026-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_421801bb7852ded99922c901b90d926c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9d191c2bb3aeda1e5a4ad4fe966854d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dbb2269fcd1893ba85573a643058f6e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_149c0274e84e0ee54d4f8db27304fbf5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60085678bcd18f42bd9c96a6f6b999dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a930841fa4d946bed78e80853782f473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50f99bebb27ba907238f8c6bda1a7445 |
| publicationDate | 2021-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2750026-C1 |
| titleOfInvention | Method for predicting targeted therapy effectiveness in patients with light cell kidney cancer |
| abstract | FIELD: medicine; oncology.SUBSTANCE: invention relates to medicine, namely to oncology, it can be used for estimating the targeted therapy effectiveness when treating patients with light cell kidney cancer, as well as monitoring of treatment of this oncological disease. The level of matrix metalloproteinase 9 (hereinafter – MMP9) in blood serum and tumor M2–pyruvate kinase (hereinafter – Tu M2–PK) in EDTA plasma is determined by immunoassay analysis before treatment and against the background of the first 2-3 cycles of the targeted therapy. If a simultaneous increase in MMP9 by at least 1.4 times and a decrease in the level of Tu M2-PK by at least 2 times are detected, then regression of tumor foci is predicted during the targeted therapy. Studies of blood serum and plasma are carried out every 6 weeks against the background of the targeted therapy.EFFECT: use of the invention makes it possible to increase the accuracy of the prediction of the targeted therapy effectiveness in patients with light cell kidney cancer, to reduce the time for obtaining the prediction, to clarify the prediction at the stages of treatment.2 cl, 3 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2800817-C1 |
| priorityDate | 2020-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 173.